The validity of atypical depression in DSM-IV

Comprehensive Psychiatry

Volumn 37, Issue 6, 1996, Pages 375-383

  Lam, Raymond W ^a   Stewart, Justine N ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MONOAMINE OXIDASE INHIBITOR;

ARTICLE; CLINICAL FEATURE; DEPRESSION; HUMAN; PSYCHOLOGIC ASSESSMENT; RELIABILITY;

EID: 0029826391     PISSN: 0010440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-440X(96)90020-6     Document Type: Article

References (66)

1. Huston PE, Locker LM. Manic-depressive psychosis. Arch Neurol Psychiatry 1948;60:37-48.
2. West ED, Dally PJ. Effect of iproniazid in depressive syndromes. Br Med J 1959;1:1491-1494.
3. Liebowitz MR, Klein DF. Hysteroid dysphoria. Psychiatr Clin North Am 1979;2:555-575.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Ed. 3. Washington, DC: American Psychiatric Association, 1980.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Ed. 3. Rev. Washington, DC: American Psychiatric Association, 1987.
6. Stewart JW, McGrath PJ, Quitkin FM, Harrison W, Markowitz J, Wager S, et al. Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo. Arch Gen Psychiatry 1989;46:1080-1087.
7. Quitkin FM, Harrison W, Liebowitz M, McGrath P, Rabkin JG, Stewart J, et al. Defining the boundaries of atypical depression. J Clin Psychiatry 1984;45:19-21.
8. Quitkin FM, Stewart JW, McGrath PJ, Tricamo E, Rabkin JG, Ocepek-Welikson K, et al. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 1993;163(suppl):30-34.
9. Stewart JW, McGrath PJ, Rabkin JG, Quitkin FM. Atypical depression. A valid clinical entity? Psychiatr Clin North Am 1993;16:479-495.
10. Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry 1970;126:983-987.
11. Kendall RE. Clinical validity. Psychol Med 1989;19:45-55.
12. Bauer MS, Dunner DL. Validity of seasonal pattern as a modifier for recurrent mood disorders for DSM-IV. Compr Psychiatry 1993;34:159-170.
13. Sargant W, Dally PJ. Treatment of anxiety states by antidepressant drugs. Br Med J 1962;1:225-227.
14. Robinson DS, Nies A, Ravaris CL, Lamborn KL. The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive-anxiety states. Arch Gen Psychiatry 1973;29: 407-413.
15. Paykel ES, Parker RR, Penrose RJ, Rassaby ER. Depressive classification and prediction of response of phenelzine. Br J Psychiatry 1979;134:572-581.
16. Sovner RD. The clinical characteristics and treatment of atypical depression. J Clin Psychiatry 1981;42:285-289.
17. Davidson JR, Miller RD, Turnbull CD, Sullivan JL. Atypical depression. Arch Gen Psychiatry 1982;39:527-534.
18. Paykel ES, Parker RR, Rowan PR, Rao BM, Taylor CN. Nosology of atypical depression. Psychol Med 1983;13: 131-139.
19. Davidson J, Zisook S, Giller E, Helms M. Symptoms of interpersonal sensitivity in depression. Compr Psychiatry 1989;30:357-368.
20. Spitzer RL, Williams JB. Hysteroid dysphoria: an unsuccessful attempt to demonstrate its syndromal validity. Am J Psychiatry 1982;139:1286-1291.
21. Beeber AR, Kline MD, Pies RW, Manring JM Jr. Hysteroid dysphoria in depressed inpatients. J Clin Psychiatry 1984;45:164-166.
22. Horwath E, Johnson J, Weissman MM, Hornig CD. The validity of major depression with atypical features based on a community study. J Affective Disord 1992;26:117-125.
23. Thase ME, Carpenter L, Kupfer DJ, Frank E. Clinical significance of reversed vegetative subtypes of recurrent major depression. Psychopharmacol Bull 1991;27:17-22.
24. Asnis GM, McGinn LK, Sanderson WC. Atypical depression: clinical aspects and noradrenergic function. Am J Psychiatry 1995;152:31-36.
25. Detre T, Himmelhoch J, Schwarzburg M, Anderson CM, Byck R, Kupfer DJ. Hypersomnia and manic-depressive disease. Am J Psychiatry 1972;128:1303-1305.
26. Casper RC, Redmond DE Jr, Katz MM, Schaffer CB, Davis JM, Koslow SH. Somatic symptoms in primary affective disorder. Arch Gen Psychiatry 1985;42:1098-1104.
27. Katz MM, Robins E, Croughan J, Secunda S, Swann A. Behavioral measurement and drug response characteristics of unipolar and bipolar depression. Psychol Med 1982; 12:25-36.
28. Thase ME, Himmelhoch JM, Mallinger AG, Jarrett DB, Kupfer DJ. Sleep EEG and DST findings in anergic bipolar depression. Am J Psychiatry 1989;146:329-333.
29. Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y, et al. Seasonal affective disorder: a description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 1984;41:72-80.
30. Thompson C, Isaacs G. Seasonal affective disorder - a British sample. Symptomatology in reference to mode of referral and diagnostic subtype. J Affect Disord 1988;14:1-11.
31. Wirz-Justice A, Bucheli C, Graw P, Kielholz P, Fisch HU, Woggon B. Light treatment of seasonal affective disorder in Switzerland. Acta Psychiatr Scand 1986;74:193-204.
32. Lam RW, Buchanan A, Remick RA. Seasonal affective disorder - a Canadian sample. Ann Clin Psychiatry 1989;1:241-245.
33. Takahashi K, Asano Y, Kohsaka M, Okawa M, Sasaki M, Honda Y, et al. Multi-center study of seasonal affective disorders in Japan. A preliminary report. J Affective Disord 1991;21:57-65.
34. Oren DA, Jacobsen FM, Wehr TA, Cameron CL, Rosenthal NE. Predictors of response to phototherapy in seasonal affective disorder [published erratum appears in Compr Psychiatry 1992;336:419]. Compr Psychiatry 1992;33: 111-114.
35. Nagayama H, Sasaki M, Ichii S, Hanada K, Okawa M, Ohta T, et al. Atypical depressive symptoms possibly predict responsiveness to phototherapy in seasonal affective disorder. J Affective Disord 1991;23:185-189.
36. Lam RW. Morning light therapy for winter depression: predictors of response. Acta Psychiatr Scand 1994;89: 97-101.
37. Krauchi K, Wirz-Justice A, Graw P. High intake of sweets late in the day predicts a rapid and persistent response to light therapy in winter depression. Psychiatry Res 1993;46:107-117.
38. Pande AC, Haskett RF, Greden JF. Seasonality in atypical depression. Biol Psychiatry 1992;31:965-967.
39. Stewart JW, Quitkin FM, Terman M, Terman JS. Is seasonal affective disorder a variant of atypical depression? Differential response to light therapy. Psychiatry Res 1990; 33:121-128.
40. Terman M, Stewart JW. Is seasonal affective disorder a variant of atypical depression: diagnostic similarities. In: SLTBR: Abstracts of the 5th Annual Meeting of the Society for Light Treatment and Biological Rhythms. Wilsonville OR: Society for Light Treatment and Biological Rhythms, 1993:21.
41. Ebert D, Barocka A. The early course of atypical depression. Eur Arch Psychiatry Clin Neurosci 1991;241:131-132.
42. Bieleski RJ, Friedel RO. Predictions of tricyclic antidepressant response. Arch Gen Psychiatry 1976;33:1479-1489.
43. Joyce PR, Paykel ES. Predictors of drug response in depression. Arch Gen Psychiatry 1989;46:89-99.
44. Quitkin F, Rifkin A, Klein DF. Monoamine oxidase inhibitors: a review of antidepressant effectiveness. Arch Gen Psychiatry 1979;36:749-760.
45. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-137.
46. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Tricamo E, Wager SG, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication. Arch Gen Psychiatry 1990;47:935-941.
47. Quitkin FM, Stewart JW, McGrath PJ, Liebowitz MR, Harrison WM, Tricamo E, et al. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988;145:306-311.
48. Quitkin FM, Harrison W, Stewart JW, McGrath PJ, Tricamo E, Ocepek-Welikson K, et al. Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design. Arch Gen Psychiatry 1991;48:319-323.
49. McGrath PJ, Stewart JW, Nunes EV, Ocepek-Welikson K, Rabkin JG, Quitkin FM, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993; 150:118-123.
50. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Wager SG, Nunes E, et al. Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression. Arch Gen Psychiatry 1989;46: 787-793.
51. McGrath PJ, Stewart JW, Harrison WM, Ocepek-Welikson K, Rabkin JG, Nunes EN, et al. Predictive value of symptoms of atypical depression for differential drug treatment outcome. J Clin Psychopharmacol 1992;12:197-202.
52. Paykel ES, Rowan PR, Parker RR, Bhat AV. Response to phenelzine and amitriptyline in subtypes of outpatient depression. Arch Gen Psychiatry 1982;39:1041-1049.
53. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res 1986;17:87-95.
54. Davidson JR, Giller EL, Zisook S, Overall JE. An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. Arch Gen Psychiatry 1988;45:120-127.
55. Davidson JR, Giller EL, Zisook S, Helms MJ. Predictors of response to monoamine oxidase inhibitors: do they exist? [published erratum appears in Eur Arch Psychiatry Clin Neurosci 1992;241:376]. Eur Arch Psychiatry Clin Neurosci 1991;241:181-186.
56. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991;148:910-916.
57. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression. IV. A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992;149:195-198.
58. Thase ME, Frank E, Mallinger AG, Hamer T, Kupfer DJ. Treatment of imipramine-resistant recurrent depression. III. Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11.
59. Larsen JK, Gjerris A, Holm P, Anderson J, Bille A, Christensen EM, et al. Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression. Acta Psychiatr Scand 1991;84:564-570.
60. Tiller J, Schweitzer I, Maguire K, Davies B. A sequential double-blind controlled study of moclobemide and diazepam in patients with atypical depression. J Affective Disord 1989;16:181-187.
61. Stratta P, Bolino F, Cupillari M, Casacchia M. A double-blind parallel study comparing fluoxetine with imipramine in the treatment of atypical depression. Int Clin Psychopharmacol 1991;6:193-196.
62. Lonnqvist J, Sihvo S, Syvalahti E, Kiviruusu O. Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affective Disord 1994;32:169-177.
63. Quitkin FM, Rabkin JG, Stewart JW, McGrath PJ, Harrison W, Davies M, et al. Sleep of atypical depressives. J Affective Disord 1985;8:61-67.
64. Harrison WM, Cooper TB, Stewart JW, Quitkin FM, McGrath PJ, Liebowitz MR, et al. The tyramine challenge test as a marker for melancholia. Arch Gen Psychiatry 1984;41:681-685.
65. Brader GE, Quitkin FM, Stewart JW, Martin C, Voglmaier MM, Harrison WM. Cerebral laterality and depression: differences in perceptual asymmetry among diagnostic subtypes. J Abnorm Psychol 1989;98:177-186.
66. Bruder GE, Towey JP, Stewart JW, Friedman D, Tenke C, Quitkin FM. Event-related potentials in depression: influence of task, stimulus hemifield and clinical features on P3 latency. Biol Psychiatry 1991;30:233-246.